Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases.

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• C3 glomerulopathy (C3G) is a rare kidney disease affecting young adults with poor prognosis.
• The disease stems from uncontrolled alternative complement pathway activation, often acquired.
• C3G serves as a model for complement-mediated kidney diseases.

Purpose of the Study:

• To review the complement activation mechanisms in C3G.
• To discuss current and emerging therapeutic strategies for C3G.
• To emphasize the potential of C3 and C3 convertase inhibition.

Main Methods:

• Review of literature on complement activation in C3G.
• Analysis of functional complement abnormalities in patients and models.
• Evaluation of therapeutic interventions targeting the complement system.

Main Results:

• The roles of C3 and C5 convertases in C3G pathogenesis are established.
• Anti-C5 therapy shows limited efficacy, indicating disease complexity.
• Targeting the C3 and C3 convertase axis presents a promising therapeutic avenue.

Conclusions:

• Understanding complement dysregulation is key to managing C3G.
• Inhibition of C3 and C3 convertase offers a novel therapeutic strategy.
• Further research into C3-targeted therapies is warranted for C3G.